CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

A majority with overweight/obesity discontinue within a year, but the rate is higher among those without type 2 diabetes.

Among over 125,000 patients, 53.6% discontinued their GLP-1 receptor agonist by 1 year, and these rates were significantly ...

Companies such as Teladoc and Omada Health have embraced GLP-1s while dangling the prospect of lowered costs to their ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.

Nearly 2 in 3 people without diabetes quit popular weight loss drugs such as Ozempic or Victoza within one year, according to ...

Discontinuation of GLP-1 receptor agonists in obesity is common, driven by weight regain and socioeconomic factors, impacting treatment effectiveness.

Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.

Taking a compounded GLP-1 medication isn’t the same thing as your pharmacy filling a cheaper, generic version of the drug ...

New poll shows about half of U.S. adults believe it is a good thing for adults to use weight-loss drugs if they are ...